Savara Inc
NASDAQ:SVRA

Watchlist Manager
Savara Inc Logo
Savara Inc
NASDAQ:SVRA
Watchlist
Price: 3.23 USD Market Closed
Market Cap: 554.3m USD
Have any thoughts about
Savara Inc?
Write Note

Savara Inc
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Savara Inc
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
Savara Inc
NASDAQ:SVRA
Change in Working Capital
-$1.6m
CAGR 3-Years
19%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Change in Working Capital
-$1.9B
CAGR 3-Years
-19%
CAGR 5-Years
-7%
CAGR 10-Years
-20%
Gilead Sciences Inc
NASDAQ:GILD
Change in Working Capital
$7.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Change in Working Capital
-$612m
CAGR 3-Years
30%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Change in Working Capital
-$793.5m
CAGR 3-Years
-13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Change in Working Capital
-$593.3m
CAGR 3-Years
28%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
No Stocks Found

Savara Inc
Glance View

Market Cap
551.8m USD
Industry
Biotechnology

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.

SVRA Intrinsic Value
2.14 USD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Savara Inc's Change in Working Capital?
Change in Working Capital
-1.6m USD

Based on the financial report for Sep 30, 2024, Savara Inc's Change in Working Capital amounts to -1.6m USD.

What is Savara Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 3Y
19%

The average annual Change in Working Capital growth rates for Savara Inc have been 19% over the past three years .

Back to Top